Immunocore Limited, a T cell receptor (TCR) biotechnology company, will present new mechanism of action data in advanced uveal and cutaneous melanoma from the tebentafusp clinical research program at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 3, 2019. Tebentafusp (IMCgp100) is a novel bispecific biologic T cell receptor therapy with an anti-CD3 immune-redirecting effector function and specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma.
“At ASCO, we will present clinical and biomarker data from our lead bispecific tebentafusp program that provide insight into its mechanism of action,” David Berman, Head of Research and Development at Immunocore, said in a company news release. “We believe these data will translate across our ImmTAC platform and provide another step towards identifying which patient populations benefit.”
Poster discussion/poster: “Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma” (Abstract #9523, Poster #94)
- Highlighting new mechanism of action results for tebentafusp (IMCgp100), this poster will be presented by Mark Middleton, MD, Head, Department of Oncology, University of Oxford, on Monday 3 June, 1:15-4:45 p.m. CDT in Hall A.
- The poster will also be discussed by Sophie Piperno-Neumann, MD, Department of Medical Oncology, Institut Curie, in the Melanoma/Skin Cancers poster discussion session on Monday 3 June, 4:30-6:00 p.m. CDT in Room E451.
Poster: “Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma” (Abstract #9530, Poster #101)
- In a retrospective analysis, reporting the potential association of rash with overall survival and temporal association of key cytokines with cytokine mediated adverse events for tebentafusp (IMCgp100), this poster will be presented by Omid Hamid, MD, Chief of Translational Research and Immunotherapy and Director of Melanoma Therapeutics, Angeles Clinic, in the Melanoma/Skin Cancers poster session on Monday 3 June, 1:15-4:45 p.m. CDT in Hall A.
Analyses presented at the meeting stemmed from a phase 1 clinical trial assessing the safety and tolerability of tebentafusp (NCT01211262).
Immunocore recently launched https://thinkuvealmelanoma.com/ aimed at physicians to help spot and screen uveal melanoma earlier.